FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.	20549
------------------	-------

ONB APPROVAL											
OMB Number:	3235-0287										
Estimated average burden											

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1(0). 30	ee instruction i	· .																		
1. Name and Address of Reporting Person*						2. Issuer Name and Ticker or Trading Symbol Axonics, Inc. [AXNX]								(Ch	Relationship of Reporting Person(s) to Issuer (Check all applicable)					
snyderman nancy lynn MD															Direct	tor		10% O	wner	
(Last) (First) (Middle) 26 TECHNOLOGY DRIVE						3. Date of Earliest Transaction (Month/Day/Year) 11/07/2024									Office below	er (give title v)		Other (sbelow)	specify	
20 IECHNOLOGI DRIVE																				
		4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line)								
(Street)		_			1										<u></u>	filed by On	e Rep	ortina Pers	on	
IRVINE	CA	A 9.	2618		1										Form filed by More than One Report					
,					1										Person					
(City)	(Sta	ate) (Z	Zip)		1															
		Tahlo	I - No	n-Deriva	tive S	Secu	ritios	Δca	uired	Die	posed of	or F	Ranc	ficia	Ilv Own	ed.				
			1 - 1101			_				D13					-		1			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day						Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (Disposed Of (D) (Instr. 3) 5)				Benefi Owned	ties cially Following	Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership				
								Code	v	Amount	(A) or (D) Pi		Price		ted action(s) 3 and 4)			(Instr. 4)		
Common Stock 11/07/2				2024		G	V	5,000	Г)	\$0.00) 14	1,944		D					
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
	_					,	_		-					<u> </u>		I	. 1		I	
1. Title of Derivative Security (Instr. 3)	rative Conversion Date Execution Date, rity or Exercise (Month/Day/Year) if any			4. Transaction Code (Instr. 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)			8. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owner Form Direct or Inc (I) (In	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code		v	(A)	(D)			Expiration Date	Title	Amo or Num of Shar	ber						

Explanation of Responses:

Remarks:

Kari L. Keese, as Attorney-in-

fact for Nancy Lynn

11/12/2024

Snyderman MD

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that the undersigned hereby constitutes and appoints each of Kari L. Keese, and Michael A. Hedge, signing singly, as the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Axonics, Inc. (the "Company"), a Form ID and Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form ID, 3, 4 or 5 and file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority or organization; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-infact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 4th day of October 2023. Nancy Snyderman /s/ Nancy Snyderman

676847.1\16367.0007 CORP:67609_1|379|A9324.00000

DOCSOC\701736v1\16367.0008 501859284 v1